Immedica Pharma acquired global rights to pegzilarginase from Aeglea BioTherapeutics, Inc. for approximately $120 million.

Spyre Therapeutics, Inc. is a biotechnology company. The Company is engaged in creating inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4B7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, and SPY230. It has nominated development candidates for SPY001 and SPY002. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4B7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a discovery-stage program focused on designing antibodies to bind to Interleukin 23 (IL-23).